CRSP News and Press, CRISPR Therapeutics AG From 01/16/24

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-ba...

2024-01-16 15:06:13 ET More on CRISPR, Vertex Pharma, etc. Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) Vertex Pharmaceuticals Is One Of Our Favorite Biotec...

2024-01-16 08:15:00 ET You'll probably have to pay an expensive premium for a slam-dunk growth stock that's almost certain to flourish over the next few years. Valuations reflect expectations, so you usually have to assume uncertainty and risk if you want to buy a stock at a steep discount....

2024-01-15 16:56:00 ET Shares of CRISPR Therapeutics (NASDAQ: CRSP) climbed 54% in 2023, according to data provided by S&P Global Market Intelligence . The biotech company is developing a number of promising gene-therapy treatments for serious illnesses, but it doesn't c...

2024-01-14 13:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) has put itself on the map of the healthcare industry as a serious player in gene editing. Now that it has an approved treatment in Casgevy, there's undoubtedly going to be more of a spotlight on the company. Gene-therapy ...

2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...

2024-01-13 05:20:00 ET After a tough 2022, Cathie Wood's investment in innovation paid off last year. The superstar investor's flagship Ark Innovation soared 67%, well surpassing the gains of the S&P 500 index. This is great, but Wood counts on taking her bets many steps further...

2024-01-11 01:40:00 ET Summary CASGEVY is a groundbreaking gene therapy, owned by CRISPR AG and Vertex specifically designed for the treatment of sickle cell disease. Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as th...

2024-01-09 23:25:04 ET CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference January 09, 2024 05:15 AM ET Company Participants Dr. Sam Kulkarni - Chief Executive Officer Conference Call Participants Wong Hooi - JPMorgan Presentatio...

2024-01-09 13:40:50 ET More on CRISPR Therapeutics, Vertex Pharmaceuticals, etc. Vertex Pharmaceuticals Incorporated (VRTX) J.P. Morgan 42nd Annual Healthcare Conference Vertex Pharmaceuticals: A Full Pipeline CRISPR Therapeutics: Therapies Of The Future Are Almost H...